HUMA News and Press, Humacyte Inc. From 08/10/25

2025-08-10 18:00:18 ET Major earnings expected before the bell on Monday include: Lithium Argentina AG ( LAC ) Ballard Power Systems ( BLDP ) Franco-Nevada Corporation ( FNV ) Perion Network Ltd. ( PERI ) Monday.com Ltd. ( MNDY ) Read the fu...

DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, Aug...

2025-07-23 14:30:48 ET More on Humacyte Humacyte: Revenue Ramp From Symvess Incoming Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript Humacyte jumps as DoD issues ECAT listing approva...

2025-07-23 13:01:29 ET Humacyte Rises 19% on First Military Sale of Bioengineered Vascular Device Humacyte, Inc. ( HUMA ) climbed 19.17% to lead the PRISM Emerging MedDevices Index after announcing its first sale of the FDA-approved Symvess(TM) bioengineered vascular graft t...

Sale follows recent Electronic Catalog (ECAT) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a com...

2025-07-08 14:00:35 ET ZyVersa Therapeutics Surges 126% on FDA Compassionate Use for Ultra-Rare Kidney Disease ZyVersa Therapeutics, Inc. ( ZVSA ) soared 125.67% to lead the PRISM Emerging Biotech Index after the FDA approved emergency compassionate use of its investigational ...

DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing appr...

2025-06-11 09:05:31 ET Humacyte ( HUMA ), the Durham, North Carolina-based biotech company founded in 2004, develops and manufacturers bioengineered human blood vessels and tissues for the treatment (repair and replacement) of various vascular conditions. They have one product in th...

DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 Pivotal Phase 3 clinical trial of the...

2025-06-09 01:57:15 ET Introduction Humacyte's stock ( HUMA ) is down 22% since my Sell rating in March. The company markets Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma. Notably, Symvess is only indicated in cases wher...